We developed a homogeneous immunoassay method to eliminate false-positive amphetamine results caused by cross-reactive substances, including over-the-counter allergy and cold medications. This method uses a neutralizing antibody that binds to amphetamines but does not bind to the labeled amphetamine conjugate used in the assay. The amount of neutralizing antibody is sufficient to reduce the assay signal resulting from authentic amphetamine and methamphetamine, but not the signal resulting from cross-reactants. This concept was implemented using the CEDIA | DAU Amphetamines assay on Hitachi 747 and 717 clinical chemistry analyzers. Urine samples were tested using the standard, unmodified reagents in one channel and reagents containing the neutralizing antibody in a second channel. The difference in rate between the two tests was calculated by the analyzer; true-positive samples showed a significantly greater decrease in assay signal in response to neutralizing antibody as compared with false-positive samples. The neutralization method was evaluated in two studies using 448 samples that tested positive in the initial CEDIA DAU Amphetamines screening test. The samples were separated into categories of 154 true-positive samples and 294 false-positive samples based upon a secondary screen with the Abbott FPIA Amphetamines assay followed by gas chromatography-mass spectrometry (GC-MS) testing using the HHS (SAMHSA) cutoff criteria. The CEDIA neutralization test successfully identified all 154 of the GC-MS confirmed positive samples. The test successfully identified as false positive 251 out of the 294 (85.4%) samples that failed to confirm by GC-MS.
Introduction
Amphetamine and methamphetamine are among the drugs of abuse for which urine drug screening is commonly performed. Testing is performed by an initial immunoassay, fol-lowed by confirmation using gas chromatography-mass spectrometry (GC-MS). A major problem with screening for amphetamines is the high frequency of false-positive samples caused by high concentrations of cross-reactive drugs used for relief of cold and allergy symptoms and drugs used for diet control (1) . The main offenders include ephedrine, pseudoephedrine, phenylpropanolamine, and phentermine (2) (3) (4) . Elimination of these cross-reacting samples by GC-MS is both labor-intensive and expensive.
Amphetamines are among the most frequently abused drugs. Screening results vary, but a 0.5% positive rate is not uncommon (5) . However, immunoassays may also report as high as a 1.0% false-positive rate. Strategies for reducing falsepositive results in assays for small-molecule drugs have included improvement of the specificity of the detecting antibody (6, 7) , addition of antibodies to absorb cross-reactive substances, and chemical modification of the interfering substance in the sample (8) . The most common method used for amphetamines involves the addition of a periodate pretreatment step that chemically cleaves [3-hydroxylamines such as ephedrine, pseudoephedrine, and phenylpropanolamine (9, 10) . However, this approach has no effect on cross-reactive substances that do not contain a periodate-sensitive functional group.
We have developed a more general method for elimination of false-positive results that is applicable to homogeneous immunoassay methods for drugs-of-abuse screening. This method relies on the fact that most cross-reactive substances must be present in high concentrations compared to the target analyte in order to give a false-positive result. For this reason, use of antibodies to absorb the cross-reactive substances is impractical. However, the addition of a limited amount of antibody to the target analyte will neutralize the signal in a true-positive sample, but will have no effect on the signal from a sample containing a high concentration of cross-reactive substance. If a neutralizing antibody is designed and selected so that it does not bind the labeled analyte conjugate in the assay, then its primary effect will be to reduce the signal resulting from the target analyte. Samples containing the drug of interest can be distinguished from false-positive samples by the difference in signal before and after the addition of the neutralizing antibody.
The neutralization method does not rely on the structure of the cross-reactive substance; it only requires that the substance be present in a high concentration relative to the target analyte. Additionally, this method does not require extraordinary specificity of the neutralizing antibody, only that this antibody be relatively specific for the target analyte and not bind the labeled analyte conjugate.
In the present study, the neutralization method was applied to the detection of false-positive amphetamine samples. The CEDIA DAU Amphetamines assay was modified to contain an absorbing antibody in the first reagent and combined with the unmodified reagents in a fully automated, dual-channel screening test on the BM/Hitachi automated analyzers. We describe results demonstrating effective discrimination of crossreactive substances and false-positive patient samples.
Experimental Procedures Materials
Phenylpropanolamine (• pseudoephedrine (+), ephedrine (• phentermine, and tyramine were obtained from Sigma Chemical (St. Louis, MO). Amphetamine and methamphetamine were purchased from Alltech (State College, PA). CEDIA DAU Amphetamines assay kits and the neutralizing antibody were obtained from Microgenics Corp. (Pleasanton, CA). Fluorescence polarization immuno-assay (FPIA) Amphetamines kits for the TDx and ADx were obtained from Abbott Laboratories (Abbott Park, IL).
Methods
The neutralization test for amphetamines was performed using the following procedure. One kit of CEDIA DAU Amphetamines reagents was reconstituted according to the manufacturer's instructions, the R1 (EA Reagent) and R2 (ED Reagent) reagents were each divided into two bottles, and neutralizing antibody (400 I~g/mL) was added to one bottle of R1 reagent. Two analyzer channels were programmed with identical test parameters for the CEDIA DAU Amphetamines assay (1000-ng/mL cutoff protocol); the unmodified reagents were assigned to the first channel, and the modified reagents were assigned to the second channel. A calculated test was programmed to give the difference in rates (t~-rate) between the first and second channel. Calibrators, controls, and patient samples were tested on both channels, and the rates from both channels and from the calculated test were printed for each test. The rate from the first channel and the tL-rate value were used for classification of each sample. If the sample rate from the first channel was less than that of the cutoff (1000 ng/mL methamphetamine) calibrator, the sample was classified as negative. A sample was presumed positive if the rate from the first channel exceeded the rate from the cutoff calibrator and the A-rate value was > 25 mAU/min. Alternatively, if the sample rate from the first channel exceeded the rate from a high (15,000 ng/mL methamphetamine) control, it was presumed positive regardless of the A-rate value and submitted for GC-MS confirmation. This criterion was used to identify samples with extremely high levels of target analyte, which could saturate the neutralizing antibody and fail to yield the expected A-rate value. Finally, a sample was classified as false positive if the rate from the first channel exceeded the rate of the cutoff calibrator (but did not exceed the rate of the high methamphetamine control) and the A-rate value was < 25 mAU/min. In some cases, the data were also evaluated using a 300-ng/mL cutoff calibrator.
Study design
Studies with unknown urine samples were conducted at MEDTOX Laboratory (St. Paul, MN) and at Laboratory Specialists, Inc. (LSI, New Orleans, LA). Urine samples that tested positive in routine screening using the CEDIA DAU Amphetamines assay with a 1000-ng/mL cutoff were selected for the studies. These samples were tested by the dual-channel neutralization test and by the Abbott FPIA method with a 1000-ng/mL cutoff. Positive results obtained using either the FPIA or dual-channel neutralization methods were confirmed by GC-MS analysis. Criteria for a positive GC-MS result were those recommended by the Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA): either amphetamine > 500 ng/mL or methamphetamine > 500 ng/mL and amphetamine > 200 ng/mL. Samples that were negative by both FPIA and dualchannel neutralization methods were classified as not containing amphetamines, and GC--MS analysis was not performed on these samples. ~,a 152 not tested ~ 0 I0 no drug presenl ~ ! 162 tota * HHS guidelines for a GC-MS "positive" result were either amphetamine > 500 ng/mL or methamphetamine > 500 ng/mL and amphetamine > 200 ng/mL. Samples below the HHS guidelines were classified as either drug present, amphetamine or methamphetamine > 100 ng/mL, or no drug present, amphetamine and methamphetamine < 100 ng/mL. Samples that were negatiave by both FPIA and dual-channel neutralization methods were presumed negative and not tested by GC-MS. * Samples were considered positive by CEDIA if the A-rate value was > 25 mAU/min. Alternatively, if the sample rate from the first channel exceeded the rate from a high (I 5,000 n~mL methamphetamine) control, it was presumed positive regardless of the A-rate value. w Samples were considered positive by FPIA if their value was determined to be > 1000-nglmL amphetamine calibrator.
Results
The principle of the neutralization test can be demonstrated using negative urine samples spiked with authentic drug or a cross-reactive substance. The signal resulting from the formation of ~-galactosidase in the CEDIA DAU Amphetamines assay is a function of amphetamine or methamphetamine concentration (Figure 1 ). The addition of neutralizing antibody dramatically reduces the assay signal from the authentic drug at all concentrations across the standard curve (0.5-5 lJg/mL). A similar concentration-dependent signal results from cross-reactive substances such as pseudoephedrine ( Figure 2 ) when a high concentration (~ 250 IJg/mL) is used. However, the response is not significantly reduced by the addition of neutralizing antibody. Table I summarizes the rate response and A-rate values of various analytes and cross-reactive substances in the CEDIA DAU Amphetamines assay and neutralizing test.
The effectiveness of the neutralization method for classification of screen-positive urine samples was tested in studies at MEDTOX Laboratory and LSI using BM/Hitachi 717 and 747 automated analyzers, respectively. In the MEDTOX study (Table II) , 110 of 300 samples were confirmed as positive by GC-MS. Of these 110 samples, 110 (100%) were correctly classified by the CEDIA dualchannel neutralization method, and 109 (99.1%) were correctly classified by the Abbott FPIA method. Of the 190 false-positive samples, the CEDIA dual-channel neutralization method correctly classified 162 (85.3%), and the Abbott FPIA method identified 153 (80.5%). Of the misclassified samples, 20 (FPIA) to 21 (CEDIA) contained amphetamine or methamphetamine by GC-MS but did not meet the criteria required for a positive result.
Similar results were obtained in the LSI study (Table III) . Of 148 samples selected, 44 were confirmed positive by GC-MS; all were correctly classified by both the CEDIA dual-channel neutralization and FPIA methods. Of the 104 false-positive samples, 89 (86%) were correctly classified by the CEDIA dualchannel neutralization method, whereas 86 (83%) were identified by the FPIA method.
Amphetamines screening is often performed using a cutoff lower than 1000 ng/mL. Additional testing was performed at LSI, with 78 samples exhibiting rates below that of the 1000-ng/mL methamphetamine cutoff calibrator, but equal to or greater than that of a 300-ng/mL calibrator. All 78 samples gave GC-MS results below the HHS (SAMHSA) cutoff levels. The CEDIA dual-channel neutralization method correctly eliminated all 78 samples as false positives, and the FPIA method eliminated 75 samples and identified 3 of the samples as requiring confirmation by GC-MS.
The distribution of A-rate values for true-and false-positive samples (Figure 3 * HHS guidelines for a GC-MS "positive" result were either amphetamine > 500 ng/mL or methamphetamine > 500 n~mL and amphetamine > 200 ng/mL. Samples below the HHS guidelines were classified as either drug present, amphetamine or methamphetamine > 100 ng/mL, or no drug present, amphetamine and methamphetamine < 100 ng/mL. t Samples which were negatiave by both FPIA and dual-channel neutralization methods were presumed negative and not tested by GC-MS. * Samples were considered positive by CEDIA if the A-rate value was _> 25 mAU/min. Alternatively, if the sample rate from the first channel exceeded the rate from a high (15,000 ng/mL methamphetamine) control, it was presumed positive regardless of the A-rate value. w Samples were considered positive by FPIA if their value was determined to be > 1000-ng/mL amphetamine calibrator.
The results of this study demonstrate the effectiveness of a novel dual-channel neutralization method for the elimination of false-positive results in drugs-of-abuse screening. This method was applied as a secondary screen of amphetaminespositive samples, identifying 85% of the samples that failed to confirm by GC-MS. The majority of the samples that remained false positive by CEDIA method (27 out of 43), contained measurable levels of amphetamines by GC-MS, but did not meet the HHS guidelines for a positive result. These guidelines were set in response to the specificity limitations of earlier GC-MS confirmation methods (11) . However, if these amphetaminescontaining samples were reclassified as positive by GC-MS, the specificity of the CEDIA method would be 95%.
The dual-channel neutralization method has a number of fundamental advantages over previous methods, such as chemical modification and immunoadsorption of cross-reactive substances. First, the neutralization method does not depend on the cross-reactant encountered, but only on the relative concentrations of analyte and cross-reactant. Thus, modifications to the procedure in response to newly discovered cross-reactive substances are not necessary. In the case of amphetamines, diet drugs such as phentermine are not eliminated by periodate pretreatment, resulting in a greater number of false-positive samples. Second, the neutralization method can be applied to immunoassay methods where the test reagents are sensitive to the chemicals used for modification of the cross-reactants. Third, the neutralization method can be fully automated on the same analyzer as is used for the initial screening method. This increases laboratory efficiency and will take advantage of future modular instrument systems and software which will automatically perform reflex testing of this type. A practical advantage of the neutralization method is the elimination of a separate analyzer for secondary testing. Typically, secondary confirmation tests for amphetamines are performed on the Abbott FPIA analyzer, which uses a periodate pretreatment. This generally requires resampling of the primary tube and inclusion of new blind specimens, with the resulting chain-of-custody issues and costs. The dual-channel neutralization method can be performed on the same sample cup as the initial screening test, with minimal delays in retesting before referral of samples to GC-MS for confirmation. In addition, maintenance of a separate instrument and training of personnel is eliminated.
In summary, the neutralization method provides a practical solution to cross-reactivity issues with immunoassay tests for amphetamines. The method can be applied as an efficient secondary screen in high-volume drug-screening laboratories or as a primary test in a hospital or emergency room for increased specificity. 
